StockData
Sarepta Therapeutics, Inc. logo

Sarepta Therapeutics, Inc. (SRPT) stock

SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3086% below fair value
$14.53−0.24 (-1.62%)

Close on Nov 18, 2026Market cap $1.53BP/E –Yield –

Sarepta Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Sarepta Therapeutics's gross profit for the twelve months ending Dec 31, 2025 was $2.17B, up 47.9% year over year. For fiscal 2025 it was $2.17B, up 40964.8% from the year before.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.17B+40964.8%
FY2016Dec 31, 2016$5.29M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$29.10M-105.8%
Q3 FY2025Sep 30, 2025$219.27M-35.1%
Q2 FY2025Jun 30, 2025$360.57M+14.1%
Q1 FY2025Mar 31, 2025$473.96M+53.4%
Q4 FY2024Dec 31, 2024$505.85M+1367.2%
Q3 FY2024Sep 30, 2024$338.08M+2001.2%
Q2 FY2024Jun 30, 2024$316.00M+5872.5%
Q1 FY2024Mar 31, 2024$308.93M–
Q2 FY2017Jun 30, 2017$34.48M–
Q1 FY2017Mar 31, 2017$16.09M–
Q4 FY2016Dec 31, 2016$5.29M–

More Sarepta Therapeutics figures

See a number that looks wrong?